The SPDR S&P Biotech ETF (XBI) has experienced a significant inflow of approximately $591 million, marking a 5.8% week-over-week increase in outstanding units, which rose from 65,325,000 to 69,100,000. This data was reported as of [insert date], highlighting strong investor interest in the ETF.
Currently, XBI’s share price stands at $159.31, within a 52-week range of $83.02 to $160.82. Among its notable components, Apogee Therapeutics Inc (APGE) is trading flat, while Kymera Therapeutics Inc (KYMR) and Twist Bioscience Corp (TWST) have seen modest increases of 0.6% and 1.2%, respectively.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
